KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Short term Debt (2016 - 2025)

Historic Short term Debt for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $1.0 billion.

  • Jazz Pharmaceuticals' Short term Debt rose 321993.23% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 321993.23%. This contributed to the annual value of $31.0 million for FY2024, which is 9487.56% down from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Short term Debt is $1.0 billion, which was up 321993.23% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Short term Debt registered a high of $1.0 billion during Q3 2025, and its lowest value of $31.0 million during Q3 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Short term Debt had a median value of $31.0 million in 2021 and averaged $279.8 million.
  • Examining YoY changes over the last 5 years, Jazz Pharmaceuticals' Short term Debt showed a top increase of 321993.23% in 2025 and a maximum decrease of 9487.92% in 2025.
  • Jazz Pharmaceuticals' Short term Debt (Quarter) stood at $31.0 million in 2021, then changed by 0.0% to $31.0 million in 2022, then soared by 1851.46% to $605.0 million in 2023, then plummeted by 94.88% to $31.0 million in 2024, then surged by 3219.93% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q3 2025, $1.0 billion for Q2 2025, and $31.0 million during Q1 2025.